Month: June 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 982,403 537.23 527,780,00710 June 2025 2,000 627.23 1,254,45011 June 2025 14,169 628.91 8,910,96512...

WISeKey Appoints Rolf Gobet to its Strategic Advisory Committee Geneva – June 16, 2025 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announced the appointment of Rolf Gobet to its Strategic Advisory Committee.Mr. Gobet brings over three decades of experience in managing complex public-private projects, as he has held several leadership roles across Europe. As part of HP’s EMEA e-government group, which focuses on providing technological solutions and services to public sector organizations in the Europe, Middle East, and Africa region, Mr. Gobet led the implementation of the world’s first internet voting solution, an achievement made possible through a close collaboration with WISeKey. This initiative set a global benchmark for digital trust...

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression Parkinson’s disease affects over 10 million people globally and significant unmet need remainsBasel, 16 June 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. “We are encouraged by the efficacy signals observed across...

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress. Notably, in multiple studies presented at this year’s EHA Annual Congress, the third-generation tyrosine kinase inhibitor (TKI) olverembatinib showed broad therapeutic potential and demonstrated particular clinical benefit in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). According to the results, olverembatinib demonstrated high complete remission...

TORONTO, June 15, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced active trading in its physically-deliverable Gold Singapore Futures following the product’s official launch on June 12, 2025. As the only physically-deliverable, U.S. dollar-denominated gold futures contract based in Asia’s primary trading center of Singapore, this product provides a regionally relevant tool for price discovery, hedging, and delivery, and offers global access to a contract designed for today’s trade flows. The Abaxx...

This record adds to the Global 7500 aircraft’s quickly growing list of records, which recently surpassed 100, and demonstrates its ability to connect key cities around the world faster than any other business jet With its signature smooth ride and industry-leading landing capabilities, the Global 7500 is the ultimate business tool to complete fast, effective missions around the worldPARIS, June 16, 2025 (GLOBE NEWSWIRE) — Bombardier is proud to announce that its flagship aircraft, the Global 7500, has set a new speed record on a mission departing from Pierre Elliott Trudeau International Airport in Montreal, and landing at Paris-Le Bourget Airport. The Global 7500, renowned for its unparalleled capabilities, logged another record with a top speed of over 1,000 km/hr during its flight to Paris and completed the record in 5 hours...

The board of directors of IDEX Biometrics ASA has resolved to issue 299,381,600 new shares at NOK 0.01 per share to employees, contractors and directors in the IDEX group (“Personnel Placement”). The purpose of the Personnel Placement is to incentivise the personnel in the implementation of the amended business plan and commercialisation of the company’s products. The Personnel Placement is according to the resolution by the extraordinary general meeting of IDEX Biometrics ASA held on 11 April 2025, where the board was authorised to issue shares on terms equivalent to the terms in the debt conversion that was approved at the same meeting. The shares are restricted for 18 months from the date of issuance and may not be sold or otherwise transferred during the restriction period. 1/3 of the shares are released from the restriction after...

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE, 15 JUNE 2025 AT 21:55 P.M. EET, INSIDE INFORMATION Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025 Oma Savings Bank Plc (OmaSp or Company) lowers its earnings guidance for 2025 as the company’s cost level is expected to remain high throughout the 2025 financial year due to investments in risk management and quality processes, increased headcount, and efforts to address the findings of the Financial Supervisory Authority’s inspection. In addition, the update to the ECL model implemented during the first quarter has increased the level of credit loss provisions more than anticipated. Furthermore, fee and commission income is expected to grow more slowly than anticipated in the prevailing economic environment. OmaSp estimates that...

PRESS RELEASEJune 15, 2025Announcement regarding the governance of Renault Group Boulogne-Billancourt, June 15,2025 – After 5 years at the head of Renault Group, Luca de Meo has announced his decision to step down and pursue new challenges outside the automotive sector. The Board of Directors, convened by its Chairman Jean-Dominique Senard, expressed their gratitude to Luca de Meo for the turnaround and transformation of Renault Group and accepted that his departure would be effective from July 15, 2025. Luca de Meo will continue to perform his duties until that date. The Board of Directors has initiated the process of appointing a new Chief Executive Officer based on the already defined succession plan. The Board of Directors has expressed its confidence in the quality and experience of the management team to continue and accelerate...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory studyNew late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammationParis and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc....